CoVac501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity

	CoVac501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity
	Long, YR; Sun, JH; Song, TZ; Liu, TT; Tang, F; Zhang, XX; Ding, LF; Miao, YQ; Zhu, WL; Pan, XY; An, Q; Qin, MA; Tong, XK; Peng, XH; Yu, P; Zhu, P; Xu, JQ; Zhang, XY; Zhang, YC; Liu, DT; Chen, B; Chen, HL; Zhang, LK; Xiao, GF; Zuo, JP; Tang, W; Zhou, J; Li, H; Xu, ZJ; Zheng, HY; Long, XY; Qin, QP; Gan, Y; Ren, J; Huang, W; Zheng, YT; Jin, GY; Gong, LK
	2022
发表期刊	CELL DISCOVERY
卷号	8 期号:1
摘要	Safe, effective, and economical vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are needed to achieve adequate herd immunity and end the pandemic. We constructed a novel SARS-CoV-2 vaccine, CoVac501, which is a self-adjuvanting peptide vaccine conjugated with Toll-like receptor 7 (TLR7) agonists. The vaccine contains immunodominant peptides screened from the receptor-binding domain (RBD) and is fully chemically synthesized. It has been formulated in an optimized nanoemulsion formulation and is stable at 40 degrees C for 1 month. In non-human primates (NHPs), CoVac501 elicited high and persistent titers of protective neutralizing antibodies against multiple RBD mutations, SARS-CoV-2 original strain, and variants (B.1.1.7 and B.1.617.2). Specific peptides booster immunization against the B.1.351 variant has also been shown to be effective in improving protection against B.1.351. Meanwhile, CoVac501 elicited the increase of memory T cells, antigen-specific CD8(+) T-cell responses, and Th1-biased CD4(+) T-cell immune responses in NHPs. Notably, at an extremely high SARS-CoV-2 challenge dose of 1 x 10(7) TCID50, CoVac501 provided near-complete protection for the upper and lower respiratory tracts of cynomolgus macaques.
收录类别	sci
语种	英语
文献类型	期刊论文
条目标识符	http://ir.kiz.ac.cn/handle/152453/13849
专题	科研部门_分子免疫药理学（郑永唐）
推荐引用方式 GB/T 7714	Long, YR,Sun, JH,Song, TZ,et al. CoVac501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity[J]. CELL DISCOVERY,2022,8(1).
APA	Long, YR.,Sun, JH.,Song, TZ.,Liu, TT.,Tang, F.,...&Gong, LK.(2022).CoVac501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity.CELL DISCOVERY,8(1).
MLA	Long, YR,et al."CoVac501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity".CELL DISCOVERY 8.1(2022).

条目包含的文件
文件名称/大小	文献类型	版本类型	开放类型	使用许可
2023041171.pdf（3023KB）	期刊论文	出版稿	开放获取	CC BY-NC-SA	请求全文